LabCorp's Drug Development Business, Covance, Acquires GlobalCare
LabCorp recently announced the company’s drug development business, Covance, has acquired GlobalCare, a globally recognized industry leader in patient-centric decentralized clinical trials support services.
This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. Specifically, Covance will leverage GlobalCare’s mobile healthcare services, site staffing support, patient transport assistance and contracted central pharmacy services, complementing and strengthening Covance’s decentralized trial capabilities.
This acquisition will benefit GlobalCare’s current and future customers by providing access to needed resources and technology to scale services to meet growing industry needs. GlobalCare will also complement its existing services with additional important decentralized clinical trial services via Covance capabilities such as eConsent, tele-health, Electronic Data Capture (EDC), online patient scheduling, connected device solutions, and more. This transaction allows for seamless integration of a full suite of biopharmaceutical services.
In November 2019, Covance launched its cohesive Decentralized Clinical Trials (DCT) solutions, which integrate unique capabilities from across the company’s leading diagnostic and drug development business units, redefining the patient experience to increase participation.
For more information about Covance and its DCT capabilities, click here.
For more information about GlobalCare, click here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
